Gene · 1814
DRD3: dopamine receptor D3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. DRD3: dopamine receptor D3. Genes, record 1814. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1814
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P35462 | Dopamine receptor D3 | 400 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents24
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 44203 | P35462 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 44204 | P35462 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 44205 | P35462 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 10980 | P35462 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 10980 | P35462 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 25461 | P35462 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 25462 | P35462 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 25463 | P35462 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 255 | P35462 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 128432 | P35462 | Espacenet |
1 to 10 of 24
See all 24 patentsDrugs48
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ABT-925 | CHEMBL439338 | Dopamine D3 receptor antagonist | ANTAGONIST | ChEMBL |
| ADOPRAZINE | CHEMBL221692 | Dopamine D3 receptor antagonist | ANTAGONIST | ChEMBL |
| AMISULPRIDE | CHEMBL243712 | Dopamine receptors; D2 & D3 antagonist | ANTAGONIST | ChEMBL |
| AMOXAPINE | CHEMBL1113 | Dopamine receptor antagonist | ANTAGONIST | ChEMBL |
| APOMORPHINE | CHEMBL53 | D2-like dopamine receptor agonist | AGONIST | ChEMBL |
| APOMORPHINE HYDROCHLORIDE | CHEMBL3187985 | D2-like dopamine receptor agonist | AGONIST | ChEMBL |
| BLONANSERIN | CHEMBL178803 | Dopamine D3 receptor antagonist | ANTAGONIST | ChEMBL |
| BROMOCRIPTINE | CHEMBL493 | D2-like dopamine receptor agonist | AGONIST | ChEMBL |
| BROMOCRIPTINE MESYLATE | CHEMBL1200503 | D2-like dopamine receptor agonist | AGONIST | ChEMBL |
| CARIPRAZINE | CHEMBL2028019 | Dopamine D3 receptor modulator | MODULATOR | ChEMBL |
1 to 10 of 48
See all 48 drugsTrials940
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07565428 | OLANZAPINE | PHASE3 | ClinicalTrials.gov | |
| NCT07480785 | DROPERIDOL | ClinicalTrials.gov | ||
| NCT07382960 | PRAMIPEXOLE | ClinicalTrials.gov | ||
| NCT07263191 | OLANZAPINE | ClinicalTrials.gov | ||
| NCT07190482 | OLANZAPINE | PHASE1 | ClinicalTrials.gov | |
| NCT07185815 | CARIPRAZINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07152184 | LEVOMEPROMAZINE | PHASE2 | ClinicalTrials.gov | |
| NCT07152184 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07152184 | HALOPERIDOL | PHASE2 | ClinicalTrials.gov | |
| NCT07152184 | CHLORPROMAZINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 940
See all 940 trialsNIH grants1,692
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | DRD3 papers | Newest fiscal year |
|---|---|---|---|
| ZIADA000424 | Novel Dopamine D3/D2 Receptor Ligands | 15 | 2025 |
| ZIANS002263 | Molecular And Pharmacological Studies Of Dopamine Receptors | 12 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 10 | 2025 |
| ZIAAA000301 | Integrative genetics of behavior with high throughput technologies | 10 | 2025 |
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 8 | 2025 |
| P30MH062512 | HIV Neurobehavioral Research Center | 6 | 2025 |
| ZIADA000606 | Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptor | 6 | 2025 |
| R01MH112205 | Molecular Details of Psychoactive Drug Actions | 5 | 2025 |
| R35GM122481 | Development and Testing of New Computational Methods for Ligand Discovery and Mechanism | 5 | 2025 |
| T32MH079785 | Interdisciplinary And Translational Research Training In Neurohiv | 4 | 2025 |
1 to 10 of 1,692Source NIH's project files
See all 1,692 nih grantsPapers2,771
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Inflammation and neuropsychiatric symptoms in Parkinson's disease: a genetic association. | Front Aging Neurosci | 2026 | 42741404 | PubTator, text mining | PubMed |
| Receptor Contribution Reallocation After Removal of Literature-Derived Weights: A Secondary Sensitivity Analysis of the Integrated Ki-DDD-TWAS Pipeline for Antipsychotic Lipid-Trait Prioritization. | Cureus | 2026 | 42540671 | PubTator, text mining | PubMed |
| Dopaminergic genetic variation and response to social comparative feedback when learning a motor sequence task. | PLoS One | 2026 | 42525625 | PubTator, text mining | PubMed |
| Analysis of genetic polymorphisms and mRNA expression of DRD3 and HTR2A in bruxism. | BMC Oral Health | 2026 | 42237294 | PubTator, text mining | PubMed |
| Biomarker Variants of Dopamine Receptor Genes Influence the Binding Interaction Between Dopamine Receptor and Risperidone. | Drug Des Devel Ther | 2026 | 42052100 | PubTator, text mining | PubMed |
| Repurposing Quetiapine as an Adjuvant Therapeutic Agent for Triple-Negative Breast Cancer. | Radiat Res | 2026 | 42019962 | PubTator, text mining | PubMed |
| Genetic evidence for causal relationship between general cognition and treatment resistance in schizophrenia. | Transl Psychiatry | 2026 | 41922311 | PubTator, text mining | PubMed |
| Safety and T1 reactivity for vasodilator stress ferumoxytol-enhanced cardiac magnetic resonance imaging. | J Cardiovasc Magn Reson | 2026 | 41864344 | PubTator, text mining | PubMed |
| Polymorphisms in GPCR genes: Their role in schizophrenia, autism diseases and response to antipsychotic treatment - A systematic review. | Prog Neuropsychopharmacol Biol Psychiatry | 2026 | 41862122 | PubTator, text mining | PubMed |
| Neuroimmunological Mechanisms of Xiao-Yao-San Against Chronic Stress-Induced Colorectal Cancer: A Bioinformatics and Single-Cell Sequencing Study. | Cancer Manag Res | 2026 | 41798904 | PubTator, text mining | PubMed |
1 to 10 of 2,771
See all 2,771 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1814
GET https://conductscience.org/api/genes/v1/1814/patents?page=2